A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL)

NCT06834789 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

132

Enrollment

INDUSTRY

Sponsor class

Conditions

Glabellar Lines

Interventions

DRUG: AGN-151586
DRUG: OnabotulinumtoxinA
DRUG: Placebo

Sponsor

AbbVie